.jpeg?crop=yes&w=340&h=340&itok=MYtmfMtU "obesity scan person"){kind=icon}
Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists. If you ar...
Press releases
-
ICON and its employees recognised as clinical research industry leaders, and for innovation and progress in sustainability
ICON was also recognised as a Top-Rated Company for Women in the 2025 Ambition Box Employee Choice Awards.
-
ICON plc Schedules Second Quarter 2025 Earnings Conference Call
ICON plc today announced that it will release its financial results for the second quarter 2025 after the market closes on Wednesday, July 23, 2025.
-
ICON releases its ICON Cares 2024 Report
The report outlines how the company is delivering on its environmental, social and governance (ESG) goals, as delivered through its ICON Cares program.
-
.jpeg?crop=yes&w=545&h=545&itok=UpkNNn2E "obesity scan person")
Global ICON survey shows need for more efficient obesity clinical trial design
ICON plc today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
ICON report first quarter 2025 results
Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue.
-
Mural Health and ICON announce partnership
Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organisation, today announce a partnership to utilise the participant management and payments platform, Mural Link.
-
ICON reports fourth quarter and full year 2024 results
Full year net business wins of $9,974 million; a net book to bill of 1.20.
-
ICON portfolio of AI tools drives clinical trial efficiencies
ICON plc today announced the expansion of its portfolio of artificial intelligence (AI) tools that deliver efficiencies across the clinical trial process, including study startup, document management, resource forecasting and metrics reporting.
-
ICON issues financial guidance for full year 2025
ICON plc today announced its financial guidance for the year ending December 31, 2025.
-
Biomarker and trial optimisation needed to drive R&D progress in Alzheimer’s and related disorders – ICON survey
ICON plc today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders.
